Topic Editors

1. Gaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel
2. Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel
1. Gaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel
2. Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel
Lysosomal Disorders Treatment and Research Program, Departments of Neurology and Psychiatry, UMass Chan Medical School, Worcester, MA 01655, USA

Advances in Gaucher Disease: A Model for Rare Lysosomal Disorders

Abstract submission deadline
closed (28 February 2023)
Manuscript submission deadline
closed (30 April 2023)
Viewed by
20154

Topic Information

Dear Colleagues,

We are excited to invite you to be part of our new Topic entitled: "Advances in Gaucher Disease: A Model for Rare Lysosomal Disorders". Gaucher disease is truly a remarkable model for rare diseases. It was among the first genetic disorders to demonstrate genotype–phenotype relationships using PCR-based methodology, and the first lysosomal storage disorder (LSD) to benefit from the orphan drug law three decades ago, and to have different therapeutic options. Although rare world-wide (1:50,000–100,000), it has a high prevenance among Ashkenazi Jews, and most of the patients with the so called "adult type" or type 1 live a normal lifespan, thereby allowing long term assessments as well as larger cohorts of patients compared to lethal disorders at a young age. There are also diverse animal models from different mice through drosophila fruit flies to zebra fish and human derived iPSCs, providing endless research opportunities. Gaucher disease was the very first lysosomal storage disease to have a safe and effective intravenous enzyme replacement therapy, to get market approval for oral substrate reduction therapy, and in addition, there are several additional treatment modalities such as pharmacological chaperones different gene therapy approaches. Still, there are many unmet needs and unresolved challenges, including the lack of treatment for the neuronopathic forms, the high cost of therapies leaving many untreated patients in poor countries, and the associations with common diseases such as various malignancies and neurodegenerative disorders, particularly Parkinson’s disease. With regard to the latter, we may be able in the near future to leverage the knowledge from Gaucher disease to the development of innovative therapies for these most common disorders, making the research of Gaucher disease all the more important. We are looking forward to receiving your contributions, and to what we believe might be an excellent up-to-date issue on all aspects of Gaucher disease, from basic science to clinical observations and therapies.

Prof. Dr. Ari Zimran
Prof. Dr. Shoshana Revel-Vilk
Prof. Dr. Edward I. Ginns
Topic Editors

Keywords

  • Gaucher disease
  • lysosomal storage disorder (LSD)
  • genetic disorders
  • animal models
  • gene therapy approaches

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Cells
cells
6.0 9.9 2012 16.6 Days CHF 2700
Current Issues in Molecular Biology
cimb
3.1 2.9 1999 13.5 Days CHF 2200
Diseases
diseases
3.7 0.8 2013 18.8 Days CHF 1800
International Journal of Molecular Sciences
ijms
5.6 8.1 2000 16.3 Days CHF 2900
International Journal of Neonatal Screening
IJNS
3.5 6.7 2015 21.3 Days CHF 1600
International Journal of Translational Medicine
ijtm
- - 2021 14.2 Days CHF 1000
Journal of Clinical Medicine
jcm
3.9 5.7 2012 17.9 Days CHF 2600
Metabolites
metabolites
4.1 5.7 2011 13.2 Days CHF 2700

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (10 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
12 pages, 1477 KiB  
Article
A Deep-Learning Approach to Spleen Volume Estimation in Patients with Gaucher Disease
by Ido Azuri, Ameer Wattad, Keren Peri-Hanania, Tamar Kashti, Ronnie Rosen, Yaron Caspi, Majdolen Istaiti, Makram Wattad, Yaakov Applbaum, Ari Zimran, Shoshana Revel-Vilk and Yonina C. Eldar
J. Clin. Med. 2023, 12(16), 5361; https://doi.org/10.3390/jcm12165361 - 18 Aug 2023
Viewed by 1183
Abstract
The enlargement of the liver and spleen (hepatosplenomegaly) is a common manifestation of Gaucher disease (GD). An accurate estimation of the liver and spleen volumes in patients with GD, using imaging tools such as magnetic resonance imaging (MRI), is crucial for the baseline [...] Read more.
The enlargement of the liver and spleen (hepatosplenomegaly) is a common manifestation of Gaucher disease (GD). An accurate estimation of the liver and spleen volumes in patients with GD, using imaging tools such as magnetic resonance imaging (MRI), is crucial for the baseline assessment and monitoring of the response to treatment. A commonly used method in clinical practice to estimate the spleen volume is the employment of a formula that uses the measurements of the craniocaudal length, diameter, and thickness of the spleen in MRI. However, the inaccuracy of this formula is significant, which, in turn, emphasizes the need for a more precise and reliable alternative. To this end, we employed deep-learning techniques, to achieve a more accurate spleen segmentation and, subsequently, calculate the resulting spleen volume with higher accuracy on a testing set cohort of 20 patients with GD. Our results indicate that the mean error obtained using the deep-learning approach to spleen volume estimation is 3.6 ± 2.7%, which is significantly lower than the common formula approach, which resulted in a mean error of 13.9 ± 9.6%. These findings suggest that the integration of deep-learning methods into the clinical routine practice for spleen volume calculation could lead to improved diagnostic and monitoring outcomes. Full article
Show Figures

Figure 1

15 pages, 639 KiB  
Article
The Spectrum of Neurological and Sensory Abnormalities in Gaucher Disease Patients: A Multidisciplinary Study (SENOPRO)
by Maria Giulia Tullo, Emanuele Cerulli Irelli, Francesca Caramia, Gianmarco Tessari, Carlo Di Bonaventura, Rosaria Turchetta, Anna Teresa Giallonardo, Giovanna Palumbo, Simona Bianchi, Francesca Atturo, Marcella Nebbioso, Patrizia Mancini, Cecilia Guariglia and Fiorina Giona
Int. J. Mol. Sci. 2023, 24(10), 8844; https://doi.org/10.3390/ijms24108844 - 16 May 2023
Cited by 5 | Viewed by 1522
Abstract
Gaucher disease (GD) has been increasingly recognized as a continuum of phenotypes with variable neurological and sensory involvement. No study has yet specifically explored the spectrum of neuropsychiatric and sensory abnormalities in GD patients through a multidisciplinary approach. Abnormalities involving the nervous system, [...] Read more.
Gaucher disease (GD) has been increasingly recognized as a continuum of phenotypes with variable neurological and sensory involvement. No study has yet specifically explored the spectrum of neuropsychiatric and sensory abnormalities in GD patients through a multidisciplinary approach. Abnormalities involving the nervous system, including sensory abnormalities, cognitive disturbances, and psychiatric comorbidities, have been identified in GD1 and GD3 patients. In this prospective study, named SENOPRO, we performed neurological, neuroradiological, neuropsychological, ophthalmological, and hearing assessments in 22 GD patients: 19 GD1 and 3 GD3. First, we highlighted a high rate of parkinsonian motor and non-motor symptoms (including high rates of excessive daytime sleepiness), especially in GD1 patients harboring severe glucocerebrosidase variants. Secondly, neuropsychological evaluations revealed a high prevalence of cognitive impairment and psychiatric disturbances, both in patients initially classified as GD1 and GD3. Thirdly, hippocampal brain volume reduction was associated with impaired short- and long-term performance in an episodic memory test. Fourthly, audiometric assessment showed an impaired speech perception in noise in the majority of patients, indicative of an impaired central processing of hearing, associated with high rates of slight hearing loss both in GD1 and GD3 patients. Finally, relevant structural and functional abnormalities along the visual system were found both in GD1 and GD3 patients by means of visual evoked potentials and optical coherence tomography. Overall, our findings support the concept of GD as a spectrum of disease subtypes, and support the importance of in-depth periodic monitoring of cognitive and motor performances, mood, sleep patterns, and sensory abnormalities in all patients with GD, independently from the patient’s initial classification. Full article
Show Figures

Figure 1

7 pages, 243 KiB  
Brief Report
The Bone Biomarker of Quantitative Chemical Shift Imaging in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long-Term Enzyme Replacement Therapy
by Ari Zimran, Jeff Szer, Michal Becker-Cohen, Sjoerd Jens, Claudia Cozma and Shoshana Revel-Vilk
J. Clin. Med. 2023, 12(6), 2220; https://doi.org/10.3390/jcm12062220 - 13 Mar 2023
Viewed by 1233
Abstract
Quantitative chemical shift imaging (QCSI) is the most sensitive imaging biomarker to assess bone marrow involvement in Gaucher disease. Widespread QCSI use is limited by test availability. Anecdotal reports describe two patients demonstrating significant improvement in fat fraction (FF) assessed by QCSI following [...] Read more.
Quantitative chemical shift imaging (QCSI) is the most sensitive imaging biomarker to assess bone marrow involvement in Gaucher disease. Widespread QCSI use is limited by test availability. Anecdotal reports describe two patients demonstrating significant improvement in fat fraction (FF) assessed by QCSI following a switch from imiglucerase to taliglucerase alfa. This analysis evaluated bone marrow involvement in adults with Type 1 Gaucher disease receiving low-dose enzyme replacement therapy (ERT) with imiglucerase and/or velaglucerase alfa. We report baseline data for 30 patients meeting eligibility criteria. Median (range) duration and dose of ERT were 18 (5–26) years and 30 (30–60) U/kg/month, respectively. Low FF scores (<0.30) were observed for seven patients (23%; 95% confidence interval, 10–42%) and were more common in females (n = 6) versus males (n = 1; p < 0.025); one female was menopausal. These baseline data demonstrate that prolonged low-dose ERT with imiglucerase or velaglucerase alfa led to an adequate bone response, assessed by QCSI, in the majority of patients. A minority of such patients with suboptimal bone response require therapeutic change. The next phase of the study will address the effect of switching to taliglucerase alfa on bone status for patients with less than optimal QCSI scores (<0.30). Full article
17 pages, 1414 KiB  
Review
Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review
by Genaro Castillon, Shun-Chiao Chang and Yola Moride
J. Clin. Med. 2023, 12(1), 85; https://doi.org/10.3390/jcm12010085 - 22 Dec 2022
Cited by 14 | Viewed by 3912
Abstract
Incidence and prevalence estimates for Gaucher disease (GD) are scarce for this rare disease and can be variable within the same region. This review provides a qualitative synthesis of global GD incidence and prevalence estimates, GD1–3 type-specific and overall, published in the last [...] Read more.
Incidence and prevalence estimates for Gaucher disease (GD) are scarce for this rare disease and can be variable within the same region. This review provides a qualitative synthesis of global GD incidence and prevalence estimates, GD1–3 type-specific and overall, published in the last 10 years. A targeted literature search was conducted across multiple databases from January 2011 to September 2020, including web-based sources and congress proceedings to May 2021. Searches yielded 490 publications, with 31 analyzed: 20 cohort studies (15 prospective, 5 retrospective), 6 cross-sectional studies, 5 online reports (most from Europe (n = 11) or North America (n = 11); one multiregional). Across all GD types, incidence estimates ranged 0.45–25.0/100,000 live births (16 studies), lowest for Asia-Pacific. Incidence of GD1: 0.45–22.9/100,000 live births (Europe and North America) and GD3: 1.36/100,000 live births (Asia-Pacific only). GD type-specific prevalence estimates per 100,000 population were GD1: 0.26–0.63; GD2 and GD3: 0.02–0.08 (Europe only); estimates for GD type unspecified or overall ranged 0.11–139.0/100,000 inhabitants (17 studies), highest for North America. Generalizability was assessed as “adequate”or “intermediate” for all regions with data. GD incidence and prevalence estimates for the last 10 years varied considerably between regions and were poorly documented outside Europe and North America. Data for GD2 and GD3 were limited. Full article
Show Figures

Figure 1

15 pages, 1375 KiB  
Case Report
Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease
by Matthew M. Gayed, Seung-Hye Jung, Erin Huggins, Eleanor Rodriguez-Rassi, Stephanie DeArmey, Priya Sunil Kishnani and Ashlee R. Stiles
Int. J. Mol. Sci. 2022, 23(23), 14938; https://doi.org/10.3390/ijms232314938 - 29 Nov 2022
Viewed by 1505
Abstract
Historically, disease burden and treatment responses in patients with Gaucher disease (GD) was assessed by monitoring clinical data, laboratory, imaging, chitotriosidase (CHITO), and other biomarkers; however, these biomarkers lack specificity and CHITO is uninformative in patients heterozygous or homozygous for the CHIT1 c.1049_1072dup24 [...] Read more.
Historically, disease burden and treatment responses in patients with Gaucher disease (GD) was assessed by monitoring clinical data, laboratory, imaging, chitotriosidase (CHITO), and other biomarkers; however, these biomarkers lack specificity and CHITO is uninformative in patients heterozygous or homozygous for the CHIT1 c.1049_1072dup24 variant. Recently, glucosylsphingosine (lyso-Gb1), a sensitive and specific GD biomarker, has been recommended for patient monitoring. Furthermore, studies measuring lyso-Gb1 and CHITO in patients on long-term treatment with enzyme replacement therapy (ERT) and/or substrate reduction therapy (SRT) reported as group data show a reduction in both analytes, yet individualized patient data are generally unavailable. We describe seven patients on long-term treatment with longitudinal clinical data with monitoring based on current treatment guidelines. We present four patients who exhibit stable disease with normalized CHITO despite elevated lyso-Gb1. We present one patient who transitioned from ERT to SRT due to lack of a clinical response with life-threatening thrombocytopenia who responded with marked improvement in platelets, and normalized levels of both CHITO and lyso-Gb1. Finally, we present two ERT to SRT switch patients with stable disease on ERT who exhibited non-compliance on SRT, one with mirrored marked elevations of CHITO and lyso-Gb1; and another with normal CHITO and platelets, but increasing lyso-Gb1 levels and enlarged spleen. These clinical vignettes highlight the role of lyso-Gb1 as a sensitive biomarker in management of patients with GD, and its further value when CHITO is normal and thus uninformative. We highlight the personalized medicine approach needed to optimize treatment outcomes and recommendations for these patients. Full article
Show Figures

Figure 1

10 pages, 1209 KiB  
Article
Brain-Derived Neurotrophic Factor (BDNF) Is Associated with Platelet Activity and Bleeding Tendency in Patients with Gaucher Disease
by David Azoulay, Mira Naamad, Dafna Frydman, Ellen Broide, Ari Zimran, Galia Stemer and Shoshana Revel-Vilk
Int. J. Mol. Sci. 2022, 23(22), 13982; https://doi.org/10.3390/ijms232213982 - 12 Nov 2022
Viewed by 1447
Abstract
Bleeding tendency, a prominent feature of patients with Gaucher disease (GD), is associated with abnormal platelet function. Brain-derived neurotrophic factor (BDNF) is a protein with neuroprotective potential stored in alpha granules of circulating platelets. Here we studied BDNF levels in 50 patients with [...] Read more.
Bleeding tendency, a prominent feature of patients with Gaucher disease (GD), is associated with abnormal platelet function. Brain-derived neurotrophic factor (BDNF) is a protein with neuroprotective potential stored in alpha granules of circulating platelets. Here we studied BDNF levels in 50 patients with type I GD (GD1) and their correlation with platelet activity and bleeding tendency. Flow cytometry was used to test unstimulated and stimulated measurement of platelet surface-activated expression of αIIbβ3 integrin, P-selectin and lysosomal-associated membrane protein (LAMP3/CD63). Serum and plasma BDNF levels were quantified using ELISA. The bleeding history was recorded by a bleeding questionnaire. Serum BDNF levels were positively correlated with platelet count and moderately correlated with unstimulated and stimulated platelet P-selectin expression. Patients with more than one bleeding manifestation were shown to have lower serum BDNF levels, albeit similar platelet count. Plasma BDNF levels were significantly elevated in splenectomized patients and showed a moderate positive correlation with stimulated platelet CD63 expression. These observations demonstrate the first association between BDNF levels in the peripheral blood with platelet dysfunction and increased bleeding manifestation. The role of measuring serum BDNF for assessing platelet alpha degranulation defects and bleeding risk in patients with GD and the general population needs further study. Full article
Show Figures

Figure 1

7 pages, 501 KiB  
Article
Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
by Majdolen Istaiti, Michal Becker-Cohen, Tama Dinur, Shoshana Revel-Vilk and Ari Zimran
J. Clin. Med. 2022, 11(21), 6265; https://doi.org/10.3390/jcm11216265 - 24 Oct 2022
Cited by 4 | Viewed by 1886
Abstract
Three types of enzyme replacement therapies (ERTs) and two substrate reduction therapies (SRTs) are approved for symptomatic patients with type 1 Gaucher disease (GD1). Eliglustat is the second SRT approved, yet the first to be approved as first-line therapy for any adult patients [...] Read more.
Three types of enzyme replacement therapies (ERTs) and two substrate reduction therapies (SRTs) are approved for symptomatic patients with type 1 Gaucher disease (GD1). Eliglustat is the second SRT approved, yet the first to be approved as first-line therapy for any adult patients with compatible CYP2D6 metabolizer genotype. Herein we report safety and efficacy data of the first 29 patients switched from ERT to eliglustat from the Gaucher Unit at Shaare Zedek Medical Center (SZMC) between 07/2017 and 06/2022; the median (range) time on ERT was 13 (0.66–30) years, and the median (range) time on eliglustat was 7 (1–52) months. Most patients switched due to oral preference or sub-optimal response to low-dose ERT. Twelve patients stopped eliglustat after a median (range) of 4 (1–18) months; 11 due to adverse events (AEs) and one due to personal request. There were no drug-related serious AEs and no drug-related cardiac events. Most AEs were mild and transient, mainly dyspepsia. Efficacy achievements were reflected by maintaining stability. We concluded that switching from ERT to eliglustat is safe if choosing the appropriate patients. Reassuring patients to tolerate early AEs may reduce discontinuation. Following the response and compliance to therapy is important to ensure long-term efficacy. Full article
Show Figures

Figure 1

13 pages, 985 KiB  
Article
A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease—Identifying Those at the Greatest Risk
by Michal Becker-Cohen, Ari Zimran, Tama Dinur, Maayan Tiomkin, Claudia Cozma, Arndt Rolfs, David Arkadir, Elena Shulman, Orly Manor, Ora Paltiel, Gilad Yahalom, Daniela Berg and Shoshana Revel-Vilk
Int. J. Mol. Sci. 2022, 23(20), 12211; https://doi.org/10.3390/ijms232012211 - 13 Oct 2022
Cited by 5 | Viewed by 1642
Abstract
Carriers of GBA1 gene variants have a significant risk of developing Parkinson’s disease (PD). A cohort study of GBA carriers between 40–75 years of age was initiated to study the presence of prodromal PD features. Participants underwent non-invasive tests to assess different domains [...] Read more.
Carriers of GBA1 gene variants have a significant risk of developing Parkinson’s disease (PD). A cohort study of GBA carriers between 40–75 years of age was initiated to study the presence of prodromal PD features. Participants underwent non-invasive tests to assess different domains of PD. Ninety-eight unrelated GBA carriers were enrolled (43 males) at a median age (range) of 51 (40–74) years; 71 carried the N370S variant (c.1226A > G) and 25 had a positive family history of PD. The Montreal Cognitive Assessment (MoCA) was the most frequently abnormal (23.7%, 95% CI 15.7–33.4%), followed by the ultrasound hyperechogenicity (22%, 95% CI 14–32%), Unified Parkinson’s Disease Rating Scale part III (UPDRS-III) (17.2%, 95% CI 10.2–26.4%), smell assessment (12.4%, 95% CI 6.6–20.6%) and abnormalities in sleep questionnaires (11%, 95% CI 5.7–19.4%). Significant correlations were found between tests from different domains. To define the risk for PD, we assessed the bottom 10th percentile of each prodromal test, defining this level as “abnormal”. Then we calculated the percentage of “abnormal” tests for each subject; the median (range) was 4.55 (0–43.5%). Twenty-two subjects had more than 15% “abnormal” tests. The limitations of the study included ascertainment bias of individuals with GBA-related PD in relatives, some incomplete data due to technical issues, and a lack of well-characterized normal value ranges in some tests. We plan to enroll additional participants and conduct longitudinal follow-up assessments to build a model for identifying individuals at risk for PD and investigate interventions aiming to delay the onset or perhaps to prevent full-blown PD. Full article
Show Figures

Figure 1

9 pages, 895 KiB  
Article
Using the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi Score in a Real-World Dataset
by Shoshana Revel-Vilk, Gabriel Chodick, Varda Shalev, Roni Lotan, Kaja Zarakowska and Noga Gadir
Int. J. Transl. Med. 2022, 2(3), 506-514; https://doi.org/10.3390/ijtm2030037 - 9 Sep 2022
Viewed by 2400
Abstract
Early and accurate diagnosis of Gaucher disease, a rare, autosomal recessive condition characterized by hepatosplenomegaly, thrombocytopenia, and anemia, is essential to facilitate earlier decision-making and prevent unnecessary tests and procedures. However, diagnosis can be challenging for non-specialists, owing to a wide variability in [...] Read more.
Early and accurate diagnosis of Gaucher disease, a rare, autosomal recessive condition characterized by hepatosplenomegaly, thrombocytopenia, and anemia, is essential to facilitate earlier decision-making and prevent unnecessary tests and procedures. However, diagnosis can be challenging for non-specialists, owing to a wide variability in age, severity of disease, and types of clinical manifestation. The Gaucher Earlier Diagnosis Consensus (GED-C) scoring system was developed by a panel of 22 expert physicians using Delphi methodology on the signs and covariables considered important for diagnosing Gaucher disease. This study aimed to use the scoring system in a real-world dataset. We applied the GED-C scoring system to 265 confirmed cases of Gaucher disease identified in the Maccabi Health Services (MHS) database from 1998 to 2022. Overall Delphi scores were calculated using features applicable to type 1 Gaucher disease. Based on all available patient data up to one year after diagnosis, the median (interquartile range (IQR)) Delphi score was 8.0 (5.5–11.5), with patients reporting up to 15 variables each. A score of 9.5 (6.5–12.5) was determined for 205 patients diagnosed from 2000 to 2022. The overall GED-C score was highly dependent on the extraction of all relevant data. The number of features collected in the MHS database was fewer than those required to achieve a high score on the GED-C score. Full article
Show Figures

Figure 1

14 pages, 1698 KiB  
Article
Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease
by Siddhee A. Sahasrabudhe, Marcia R. Terluk, Kyle D. Rudser, James C. Cloyd and Reena V. Kartha
Int. J. Mol. Sci. 2022, 23(16), 9189; https://doi.org/10.3390/ijms23169189 - 16 Aug 2022
Cited by 2 | Viewed by 1709
Abstract
The lack of reliable biomarkers is a significant challenge impeding progress in orphan drug development. For appropriate interpretation of intervention-based results or for evaluating candidate biomarkers, other things being equal, lower variability in biomarker measurement would be helpful. However, variability in rare disease [...] Read more.
The lack of reliable biomarkers is a significant challenge impeding progress in orphan drug development. For appropriate interpretation of intervention-based results or for evaluating candidate biomarkers, other things being equal, lower variability in biomarker measurement would be helpful. However, variability in rare disease biomarkers is often poorly understood. Type 1 Gaucher disease (GD1) is one such rare lysosomal storage disorder. Oxidative stress and inflammation have been linked to the pathophysiology of GD1 and validated measures of these processes can provide predictive value for treatment success or disease progression. This study was undertaken to investigate and compare the extent of longitudinal biological variation over a three-month period for various blood-based oxidative stress and inflammation markers in participants with GD1 on stable standard-of-care therapy (N = 13), treatment-naïve participants with GD1 (N = 5), and in age- and gender-matched healthy volunteers (N = 18). We utilized Bland–Altman plots for visual comparison of the biological variability among the three measurements. We also report group-wise means and the percentage of coefficient of variation (%CV) for 15 biomarkers. Qualitatively, we show specific markers (IL-1Ra, IL-8, and MIP-1b) to be consistently altered in GD1, irrespective of therapy status, highlighting the need for adjunctive therapies that can target and modulate these biomarkers. This information can help guide the selection of candidate biomarkers for future intervention-based studies in GD1 patients. Full article
Show Figures

Figure 1

Back to TopTop